Avanos Medical ended fiscal 2025 with fourth-quarter revenue of $180.9 million, ahead of analyst consensus estimates of $169 million and up 0.7% from the same period a year earlier. Adjusted earnings per share of $0.29 beat the $0.25 consensus. Full-year net sales reached $701.2 million, a 1.9% gain over 2024.
The headline numbers sit alongside a more complicated picture. A $77 million goodwill impairment charge in the second quarter produced a GAAP diluted loss per share of $1.57. Free cash flow fell to $43.1 million from $82.9 million the prior year. Chief Executive David Pacitti said the results demonstrated “meaningful progress on our strategic priorities” and that “organic growth remains healthy and positions us well for 2026.”
Two Segments, Different Trajectories
Avanos runs two revenue segments that moved at different speeds in the fourth quarter. Specialty Nutrition Systems, which covers enteral feeding tubes and neonatal feeding products sold under brand names including Mic-Key and NeoMed, posted revenue of $115.1 million, up 8.7% year over year. The Pain Management and Recovery segment, which includes cryoanalgesia devices and ambulatory infusion pumps for drug-free pain delivery, contributed $61.6 million, up 1.3%.
Specialty Nutrition is the faster-growing half of the business and delivered the cleaner result in the period. Pain Management grew, but modestly, even as the external policy environment around non-opioid treatment has continued shifting. Whether that segment can translate favorable regulatory and reimbursement conditions into more visible top-line acceleration remains one of the operative questions for 2026. Management guided revenue to a range of $700 million to $720 million and adjusted EPS to $0.90 to $1.10 for the year.
Portfolio Reshaping
During 2025, Avanos divested its Respiratory Health division for $110 million and sold its Game Ready rental assets, while acquiring Nexus for $27 million plus contingent payments to expand its vascular access capabilities. A transformation initiative announced alongside those moves is expected to generate $15 million to $20 million in annualized cost savings by the end of 2026.
The net effect is a leaner company with a more concentrated product focus. Avanos is no longer a respiratory health company. It operates fully within specialty nutrition and non-opioid pain. That narrower scope creates more direct exposure to any softness in either segment, but it also makes the underlying performance of each business easier to read quarter to quarter.
Reimbursement and Policy Shifts
The policy backdrop for device-based pain management has grown more favorable by several measures. The CDC’s 2022 Clinical Practice Guideline for Prescribing Opioids for Pain stated that “nonopioid therapies are preferred” for subacute and chronic pain, pushing clinicians toward maximizing nonpharmacologic treatments. The FDA issued draft guidance in September 2025 specifically to help sponsors develop non-opioid analgesics for chronic pain. On reimbursement, CMS finalized separate payment for qualifying non-opioid pain therapies in hospital outpatient departments and ambulatory surgical centers beginning in 2025, under provisions of the NOPAIN Act.
These shifts do not produce immediate revenue gains. Hospital formularies, physician behavior, and payer coverage all move slowly. But they create durable directional pressure that benefits companies operating in device-based, drug-free pain delivery, the precise category where Avanos concentrates its Pain Management segment. For a company rebuilding around two core franchises, that policy tailwind is worth tracking even when it doesn’t show up in a single quarter’s numbers.
Institutional Context
Armistice Capital held a position in Avanos Medical during 2025, alongside T. Rowe Price Investment Management, Millennium Management, and Ameriprise Financial among the company’s reported institutional holders. Avanos carries a mid-cap medical device profile that draws both dedicated healthcare funds and broader institutional holders tracking developments in the non-opioid pain space.
The 2026 guidance implies roughly flat to modest growth at the midpoint, which management attributed to measured expectations for Pain Management recovery rather than any assumption of declining demand. Specialty Nutrition continues to carry more of the near-term growth burden, a pattern that has held for several quarters and is baked into the outlook management set for the year. Broader institutional holders tracking the non-opioid pain device space have kept positions through the portfolio transition.
.